3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Breast
1
Conditions
Melanoma
98
Carcinoma, Non-Small-Cell Lung
32
Neoplasms
22
Neoplasm Metastasis
14
Carcinoma, Renal Cell
13
Prostatic Neoplasms
12
Lung Neoplasms
12
Small Cell Lung Carcinoma
10
Diabetes Mellitus, Insulin-Dependent, 12
10
Pancreatic Neoplasms
7
Uveal Melanoma
6
Skin Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Advanced Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma
5
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Kidney Neoplasms
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Breast Neoplasms
4
Various Advanced Cancer
3
Interventions
Sorafenib
23
Bevacizumab
11
Radiosurgery
6
Capecitabine
6
Radiofrequency Ablation
5
Oxaliplatin
5
Fluorouracil
5
Doxorubicin
5
pembrolizumab
4
Sunitinib
4
Erlotinib Hydrochloride
4
Cisplatin
4
Ramucirumab
3
Radiotherapy
3
Nivolumab
3
Leucovorin
3
Carboplatin
3
tremelimumab
2
spartalizumab
2
perflutren
2
derazantinib
2
carotuximab
2
Mitomycin
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Ipilimumab
2
Immunohistochemistry
2
Gemcitabine
2
Folfox protocol
2
Fluorodeoxyglucose F18
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Liver Neoplasms
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT04340193
2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3
Completed
26 enrolled
15 charts